Stock Market Update - February 24, 2026
Today's stock market saw some significant movers. Here's a breakdown of 5 stocks that caught our attention:
1. ATXI - Avenue Therapeutics, Inc.
Price: $0.2888 | Change: +92.41% ($0.1387)
ATXI saw an impressive 92.41% gain recently following a major announcement. Avenue Therapeutics, Inc. revealed an exclusive worldwide licensing agreement with Duke University for their investigational drug, ATX-04. This deal grants Avenue global rights to develop and commercialize ATX-04 as a potential treatment for Pompe disease and other rare neuromuscular conditions.
What makes this particularly significant is that ATX-04 comes with existing U.S. FDA orphan drug designation and has already shown promising early human proof-of-concept data from a Duke-led study. The data indicated potential improvements in physical abilities and a reduction in disease markers for Pompe patients.
This strategic partnership positions Avenue Therapeutics to advance a late-stage therapy that could enhance outcomes for patients with Pompe disease, strengthening the company's presence in the rare neuromuscular disease market.
2. EDSA - Edesa Biotech, Inc.
Price: $1.51 | Change: +67.96% ($0.611)
EDSA surged an impressive 67.96% after Edesa Biotech, Inc. announced positive additional data from a Phase 3 study of its drug candidate, paridiprubart. This investigational drug, aimed at Acute Respiratory Distress Syndrome (ARDS), showed a statistically significant reduction in 28-day mortality across a broad patient population.
Specifically, paridiprubart reduced the adjusted 28-day mortality to 24% compared to 33% for placebo, representing a 27% relative reduction in the risk of death. These benefits were consistent across different patient groups, including those with serious comorbidities.
What makes this particularly interesting is that following these promising results, the company has filed provisional patent applications for the drug's use in other critical conditions like sepsis and pneumonia. Edesa Biotech is also actively engaging in regulatory discussions and exploring strategic collaborations, hinting at a potentially broader impact for paridiprubart moving forward.
3. ANPA - Rich Sparkle Holdings Limited Ordinary Shares
Price: $12.51 | Change: +52.93% ($4.33)
ANPA saw a remarkable 52.93% gain, experiencing a significant stock surge around late February 2026. This upward movement was primarily driven by a combination of strategic partnerships, a major acquisition, and a private placement deal, all contributing to heightened investor optimism.
A major catalyst was their strategic partnership with Open Campus and Animoca Brands, focusing on blockchain education with up to $50 million in investments. This was followed by the acquisition of TikTok icon Khaby Lame's core company for a notable $975 million. Adding to this positive momentum, a $39 million private placement deal at $13 per share indicated strong investor confidence, providing capital for business development and European market expansion.
What makes ANPA's ascent particularly interesting is the diverse nature of these catalysts. From advancing blockchain education and leveraging a global influencer's brand to securing significant capital for expansion, these combined factors highlight an ambitious growth strategy that has clearly resonated with the market.
4. BNAI - Brand Engagement Network, Inc.
Price: $28.2 | Change: +40.23% ($8.09)
BNAI:NASDAQ just posted an impressive 40.23% gain, with a significant rise around late February 2026. This surge was primarily driven by the company's strategic decision to terminate a $50 million Standby Equity Purchase Agreement (SEPA). This move was seen by investors as a strong step to strengthen Brand Engagement Network's balance sheet and reduce potential share dilution, optimizing its capital structure.
Further boosting market confidence were several other financial and operational developments. The company announced a $1.518 million premium private placement, received over $818,000 from warrant exercises, and fully repaid legacy loans. Additionally, an exclusive $2.05 million AI licensing partnership in Africa with Valio Technologies expanded their market reach and provided new intellectual property licensing revenue.
What makes BNAI's movement particularly interesting is this combination of aggressive financial house-cleaning—by reducing potential dilution and settling debts—alongside strategic business expansion with its AI technology. This dual focus on both internal financial health and external growth opportunities appears to have been a powerful catalyst for the stock's upward momentum.
5. CLVT - Clarivate Plc
Price: $2.35 | Change: +39.88% ($0.67)
CLVT recently saw its stock price jump by a significant 39.88%. This impressive move followed Clarivate Plc, a global intelligence provider, reporting surprisingly strong financial results for the fourth quarter of 2025. The company exceeded analyst expectations for both its earnings per share and revenue, showing a healthier performance than anticipated.
Adding to the positive sentiment, Clarivate also provided an optimistic forecast for its 2026 fiscal year, projecting earnings per share notably higher than what experts had predicted. A major catalyst for investor confidence was the announcement that Clarivate is exploring the sale of its Life Sciences & Healthcare business.
This strategic move, combined with plans for free cash flow growth and share repurchases, signals a clear focus on refining their business model and creating more value for shareholders. These combined factors played a key role in the stock's upward momentum.
This analysis was generated using AI and real-time stock data. Always do your own research before making investment decisions.